- Medical College of Georgia research shows beneficial effects from use of CBD oil to treat COVID-19 symptoms
- CBD oil found to increase apelin levels in the human body, a key peptide needed to reduce lung inflammation resulting from COVID-19
- PacRoots Cannabis specializes in developing premium quality strains, including plants with high CBD content, rare terpene contents, which could potentially be used for medicinal purposes
Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) has developed a strong reputation within the global cannabis sector for producing premium quality strains and products through the employment of a meticulous, genetics-focused approach towards harvesting its crops. Following a remarkable study into the potential beneficial effects of CBD oil, the Canada-based cannabis manufacturer may potentially find itself at the forefront in the development of a remedial drug in the battle against COVID-19 (https://nnw.fm/VUkqw).
Cytokine, a type of protein secreted by immune cells in response to inflammation and infection, has been found to regulate the maturation, growth, and responsiveness of particular cell populations – thereby playing an important role in the human body’s immune systems. However, an overactive cytokine response resulting from a potentially acute case of COVID-19 could also result in severe patient lung damage and, in certain cases, even lead to death.
Researchers have found that a naturally occurring peptide called Apeline, which is traditionally produced in the heart, lungs, brain and blood and works as a key regulator in helping to normalize blood pressure and inflammation within the human body, may act as a suitable foil to cytokine.
A recently published study carried out by scientists at the Medical College of Georgia and Dental College of Georgia (https://nnw.fm/VanYX) found that CBD oil was shown to habitually increase apelin levels, in addition to improving blood oxygen content and reducing inflammation – and thus, the lung damage incurred through cytokine activity.
In the study, scientists investigated a disease called adult respiratory distress syndrome (“ARDS”), the effects of which can result in similar lung tissue damage to that seen in severe COVID-19 cases. In the studies, blood levels of apelin were found to drop to almost zero in the midst of the disease but increased nearly twenty-fold when CBD was administered.
“CBD almost brought it back to a normal level,” stated Dr Jack Yu from the Medical College of Georgia when elaborating on the effects of CBD usage on apelin levels present in the human bloodstream.
While researchers were cautious on the study’s results given the need for further in-depth research into the field, it was evident that there was a strong existing correlation between ARDS and the role of apelin in reversing lung tissue damage, as well as the benefits of increasing apelin levels through CBS treatment (https://nnw.fm/T6Pae).
Pac Roots Cannabis has been a pioneer within the cannabis sector in terms of improving and modifying the genetic make-up of their cannabis product, most recently through a strategic licensing agreement with Phenome Once Corp. The agreement granted Pac Roots access to one of Canada’s largest live genetic cannabis libraries with lab and field-tested, selectively bred seedlings. The Company has employed these to grow, breed and clone its own unique brands.
The tie-up has enabled Pac Roots to offer its customers a remarkable portfolio of over 350 meticulously designed cultivars, including CBD-dominant plants possessing rare terpene profiles. Due to its specialty CBD plant offerings, Pac Roots appears well positioned to benefit from CBD’s positive effects on assuaging COVID-19 complications.
For more information, visit the company’s website at www.PacRoots.ca.
NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://nnw.fm/PACR
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
No comments:
Post a Comment